Effectiveness of COVID-19 vaccines

Del Pilar Castañeda-Rodriguez K.; Gamboa-Cruzad J.; Montero J.N.; Villavicencio L.I.; Zavala-Gutierrez A.A. · Boletin de Malariologia y Salud Ambiental (2022) · DOI: 10.52808/bmsa.7e6.624.012

Resumen

The SARS-CoV-2 pandemic has generated considerable efforts in the development of vaccines, to verify their effectiveness, clinical trials are required and use them in the population worldwide. A systematic literature review (RSL) of COVID-19 and its impact on vaccine development was carried out from 2019 to 2022. The search strategy managed to obtain 8,646 articles, chosen from the 6 research sources (Wiley Online Library, Taylor & Francis, THE LANCET Infectious Diseases, National Library of Medicine, Nature Portfolio and Oxford Academic), then a 4-stage filter was performed with 2 exclusion criteria each, leaving only 78 articles, which were used to answer three research questions posed. In the scientific articles analyzed, the most referenced laboratories that developed Pfizer/BioNTech, Moderna, AstraZeneca, Sinovac, Sinopharm and Sputnik V vaccines were identified, the use of nanotechnology in the design of the vaccines was identified, mainly using messenger RNA, viral vector and protein subunits, depending on the case with adjuvants that enhance immunogenicity. The studies demonstrated good effectiveness, in the different prioritized groups and thanks to the dosage of the immunizations against COVID-19, the number of serious cases and therefore the mortality rate have been prevented. However, health promotion and education is recommended for the general population to encourage acceptance.

Instituciones: Universidad Nacional Mayor de San Marcos; Universidad Nacional de Trujillo